Moderna has given the first doses of its experimental
Covid-19 vaccine to participants in what will be a
30,000-person trial, as the US moved into a new phase of the race
to develop a vaccine by the start of next year.
The Boston-based biotech said on Monday that it had begun the
first Phase III study of a vaccine in the US, a large-scale trial
that is usually the last before a new product is submitted for
The company’s shares were up as much as 10.6 percent before
paring some of their gains.
Source: FS – All – Science – News
Moderna begins first late-stage US trial of COVID-19